BPC-157: Mechanisms of Tissue Repair and Gastrointestinal Healing

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid peptide (GEPPPGKPADDAGLV) derived from a protective protein in human gastric juice, studied in more than 200 published preclinical papers since the early 1990s.

Nitric Oxide Pathway Modulation

The most consistently replicated mechanism involves eNOS upregulation and simultaneous iNOS modulation. Sikiric P et al. (*Journal of Physiology and Pharmacology*, 2016) showed that BPC-157 preserves intestinal microcirculation — in rat anastomosis failure models, dehiscence rates dropped from ~80% in controls to under 20% in treated groups via NO-mediated vascular protection.

VEGF-Dependent Angiogenesis

BPC-157 upregulates VEGF and VEGFR2, driving angiogenesis in poorly vascularised structures. In a transected rat Achilles tendon study (Brcic L et al., *Journal of Orthopaedic Research*, 2018):

• Tendon tensile strength at day 14: ~80% of healthy tendon vs ~45% in controls
• Capillary density at repair site: 2.3-fold higher than controls by day 7
• Collagen fiber organisation: significantly improved at all time points

This VEGF upregulation also explains BPC-157's observed benefits in bone fracture healing, where neovascularisation of the callus is rate-limiting for mineralisation.

Growth Hormone Receptor Upregulation

BPC-157 upregulates GH receptors in healing tissue, amplifying local response to endogenous GH — an effect that complements but differs from peptides like Ipamorelin or CJC-1295 (no DAC) that increase pituitary GH secretion. By sensitising target tissues to GH, BPC-157 enhances collagen synthesis without requiring exogenous secretagogues.

Gastrointestinal Cytoprotection

In indomethacin-induced gastric ulcer models, BPC-157 at 10 ng/kg reduced ulcer area by more than 70% vs vehicle (Sikiric P et al., *Current Pharmaceutical Design*, 2018). Key mechanisms:

• Stimulation of mucus secretion from goblet cells
• COX-2 upregulation in cytoprotective context
• Suppression of TNF-alpha and IL-6
• Preservation of prostaglandin E2 synthesis

In TNBS-induced colitis rats, 4-week BPC-157 treatment normalised colon weight, stool consistency, and histological inflammation scores — findings replicated in at least four independent published studies.

Neural Repair

In sciatic nerve crush models (Sikiric P et al., *Brain Research Bulletin*, 2016), rats on BPC-157 recovered full hindlimb reflex function in 14±2 days vs 28±4 days in controls. The mechanism involves VEGF-driven reangiogenesis of the nerve sheath combined with anti-apoptotic Schwann cell protection.

Research Dosing Context

Preclinical literature uses 2-10 mcg/kg intraperitoneally or subcutaneously. Body surface area scaling to 75 kg human yields roughly 80-250 mcg total dose. Oral administration is effective for GI endpoints; subcutaneous injection for systemic healing.

All dosing information is from preclinical research only. BPC-157 is not approved for human use. For tissue repair research, TB-500 operates through a complementary actin-regulatory mechanism and is often studied alongside BPC-157.

<!-- deep-links-v1 -->

Related GI and Systemic Healing Peptides

BPC-157's gastrointestinal mechanisms connect to a broader range of gut-protective and vascular repair peptides. Larazotide Acetate (AT-1001) targets tight junction proteins to reduce intestinal permeability — a mechanism that complements BPC-157's mucosal healing and makes it relevant to leaky gut research. GLP-2, an intestinal growth hormone secreted by L-cells, promotes mucosal growth and is studied alongside BPC-157 for enterocyte proliferation. VIP (Vasoactive Intestinal Peptide) coordinates smooth muscle relaxation, secretion, and immune tolerance in the gut — overlapping functionally with BPC-157's anti-inflammatory GI actions. Substance P modulates gut motility and pain signaling through NK1 receptors, making it a relevant comparator in visceral healing models. CGRP (Calcitonin Gene-Related Peptide) coordinates neuropeptide-mediated vascular dilation in healing tissue, relevant to BPC-157's angiogenesis research.

Cardiovascular and Connective Tissue Repair

Angiotensin (1-7) exerts anti-inflammatory, vasodilatory effects through the Mas receptor — a counterregulatory axis to angiotensin II that parallels BPC-157's NO-modulating vascular effects. Bradykinin is an endogenous vasodilatory kinase-pathway peptide studied in the context of wound healing perfusion. ANP (Atrial Natriuretic Peptide) regulates vascular tone and fluid balance in healing tissue, relevant in cardiac and renal repair models. Cardiogen, a cardiac bioregulator tetrapeptide, is studied for myocardial tissue protection in the same cardioprotective research space. Klotho Peptide, derived from the aging-suppressor protein, shows renal and cardiovascular protective properties in fibrosis models. Vesugen, a vascular bioregulator tripeptide, is studied for endothelial function restoration alongside BPC-157 in vessel injury models. Cartalax, a cartilage bioregulator, extends the healing peptide landscape to joint tissue.